Kyverna to present new CAR T-cell therapy data at EULAR 2024 By Investing.com

EMERYVILLE, Calif. – Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company, announced its plans to present comprehensive data on KYV-101, its leading CAR T-cell therapy candidate, at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2024 symposium. The data encompass the treatment of 50 patients with autoimmune diseases and highlight KYV-101’s safety and early efficacy.

The symposium, “Anti-CD19 CAR T-Cell Therapy in Rheumatologic Autoimmune Diseases and Beyond,” is scheduled for June 14, from 8:15 a.m. to 9:30 a.m. CEST. It will include insights from clinical trials and patient experiences, focusing on the therapy’s application in rheumatology and neurology. Renowned experts such as Dr. Gerhard Krönke and Dr. Peter A. Merkel are among the speakers.

KYV-101, an autologous, fully human anti-CD19 CAR T-cell immunotherapy, has been administered to patients across the United States and Germany, demonstrating a differentiated safety profile. The symposium will also feature a one-year follow-up of the first patient treated with KYV-101 for myasthenia gravis.

Additionally, Kyverna will present two posters on June 12, detailing preclinical developments of its allogeneic product candidate, KYV-201, and proteomic markers for CAR T therapeutic response in autoimmune diseases.

The company’s CEO, Peter Maag, Ph.D., highlighted the growing interest in cell therapies for B cell-driven autoimmune diseases and expressed confidence in the potential of KYV-101 to change treatment paradigms.

Kyverna will also hold a press conference on the same day at 5pm CEST, featuring members of its Scientific Advisory Board, to discuss the findings further.

KYV-101 was originally designed by the National Institutes of Health (NIH) and tested in Phase 1 oncology trials. The therapy is currently under evaluation in Phase 1/2 and Phase 2 trials for various autoimmune conditions, including multiple sclerosis and lupus nephritis.

This announcement is based on a press release statement from Kyverna Therapeutics.

InvestingPro Insights

As Kyverna Therapeutics, Inc. (Nasdaq: KYTX) gears up to present its CAR T-cell therapy candidate at the EULAR 2024 symposium, the financial metrics and analyst insights provide a broader view of the company’s market position. With a market capitalization of $583.78 million, KYTX is navigating the biopharmaceutical landscape with a focus on innovation in autoimmune disease treatment. The company’s commitment to advancing KYV-101 is mirrored in its recent 8.06% return over the past week, signaling investor interest surrounding the upcoming symposium and the therapy’s potential.

However, it’s important to note that KYTX holds a negative P/E ratio of -1.09, reflecting concerns about profitability. Analysts have also revised their earnings downwards for the upcoming period, which could indicate caution about the company’s near-term financial performance. With gross profit margins in the negative at -$63.69 million for the last twelve months as of Q1 2024, and an anticipated drop in net income this year, the financial outlook presents challenges despite the scientific progress.

Investors considering KYTX will find value in the InvestingPro Tips, which reveal that the company does not pay a dividend and has not been profitable over the last twelve months. Additionally, the stock has seen a significant price drop over the last three months, now trading at 37.96% of its 52-week high. For a more comprehensive analysis and additional insights, there are 10 more InvestingPro Tips available, which can be accessed with the InvestingPro product. For those interested, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.